小诺米星治疗急性细菌性感染156例

Micronomicin in treating the acute bacterial infections in 156 patients

作者对细菌感染性疾病患者220人(男94,女126,平均年龄34±SD14yr),其中82例肌肉注射小诺米星(小诺霉素micronomicin,MCR);74例静脉滴注MCR,成人剂量均为120-180mg/d;儿童为3-4mg/(kg·d),疗程5-14d。其余64例肌注庆大霉素(GM)作为对照组。3组的显效率分别为85％,88％,86％,无显著差异。MCR耳毒性甚小而体外抑菌试验证明对革兰阴性菌敏感率(83％)显著地高于GM(69％)是其优点。

Micronomicin (MCR) is one of aminoglycoside antibiotics with little toxicity to the kidney and auditory organs. The author compared MCR and gentamicin (GM) in a prospective clinical study of the treatment of 220 patients (M 94, F 126, age 34 ±SD 14 yr) with various infectious diseases. MCR (120-180mg/d for adult) was given by iv drip and im to 82 and 74 patients respectively in a course of 5-14 d. To the rest, 64 patients, GM was given by im in same dosage and course as a control group. The results showed that the marked response rates were close to 85%, 88%, 86% respectively and no statistical significance was found among the three groups. There were no changs in ECG, liver and kidney functions as well as the vestibular function and electric audiome try in the two MCR groups, but it was found that 5/42 patients decreased 10 to 20 dB with electric audiometry after the course in the GM group. The inhibiting test of MCR to the clinically isolated Gram negative bacteria in vitro revealed that the rate of sensitivity (83%) was more remarkable than that of GM (69%). The clinical pharmacokinetic parameters of MCR in im and iv drip by determing the blood level in 17 cases are reported in this paper.